Welcome to our dedicated page for Corbus Pharmaceu news (Ticker: CRBP), a resource for investors and traders seeking the latest updates and insights on Corbus Pharmaceu stock.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is a clinical-stage biopharmaceutical company advancing targeted therapies in precision oncology and metabolic disorders. This page serves as the definitive source for CRBP news, offering investors and researchers timely updates on scientific advancements and corporate developments.
Access verified information on clinical trial progress, regulatory milestones, and strategic partnerships across CRBP's pipeline. Key focus areas include Nectin-4 targeting antibody-drug conjugates, TGFβ pathway inhibitors, and novel obesity treatments designed to address critical unmet medical needs.
Our curated news collection enables efficient tracking of CRBP's innovative approaches to drug development. Stay informed about emerging data from studies evaluating CRB-701 in solid tumors, CRB-601's impact on tumor microenvironments, and CRB-913's potential in weight management.
Bookmark this page for direct access to official press releases and third-party analyses. Regular updates ensure you maintain current awareness of CRBP's position at the forefront of precision medicine development.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced that CEO Yuval Cohen, Ph.D., will present a corporate update at the 45th Annual Goldman Sachs Global Healthcare Conference in Miami Beach, FL, from June 10-13, 2024. The presentation is scheduled for June 12, 2024, at 2:40 p.m. ET. Investors will have the opportunity to participate in one-on-one meetings with the CEO. The presentation will be webcast.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced that an abstract titled 'Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701)' will be presented at the 2024 ASCO Annual Meeting. This presentation will occur on June 1, 2024, and will provide updated clinical data from a Phase 1 trial. The trial involves dose escalation spanning seven levels and employs a Bayesian Optimal Interval design. The study aims to establish the Maximum Tolerated Dose (MTD) and Phase 2 dose for SYS6002 (CRB-701) in patients with advanced solid tumors unresponsive to standard treatments. Key findings include safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity. The study is conducted in China by Corbus's partner CSPC, with a parallel Phase 1 study recently initiated in the U.S., where the first patient was dosed in April 2024.
Corbus Pharmaceuticals Holdings, Inc. will partake in the 2024 RBC Capital Markets Global Healthcare Conference. Yuval Cohen, the CEO, will engage in a fireside chat and investor meetings on May 14-15, 2024, in New York. The event will include a webcast on May 14 at 9:30 a.m. ET.
Corbus Pharmaceuticals reported its first-quarter 2024 financial results, highlighting the dosing of the first patient in the U.S. Phase 1 clinical trial of CRB-701, targeting Nectin-4. The company raised $116 million in capital, extending its cash runway through Q1 2027, and appointed Dr. Dominic Smethurst as Chief Medical Officer. CRB-701 Phase 1 data will be presented at ASCO Annual Meeting on June 1, 2024.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) will participate in the BTIG Obesity Health Forum with CEO Yuval Cohen joining a panel discussion on CB1 Axis Therapies for Obesity on May 8, 2024. The event will be held virtually, offering insights into the company's innovative approaches to addressing obesity.
FAQ
What is the current stock price of Corbus Pharmaceu (CRBP)?
What is the market cap of Corbus Pharmaceu (CRBP)?
